Market news

There are good reasons behind analyst's bullish views of this biotech stock.

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 14.22% on an annualized basis producing an average annual return of 26.19%. Currently, argenx has a market capitalization of $59.17 billion.

argenx (ENXTBR:ARGX) drew fresh attention after its Extraordinary General Meeting confirmed Thomas M. Brakel and Khurem Farooq as new non-executive directors, prompting investors to reassess how board composition might influence longer term decision making. argenx shares trade at €835.8 after a modest pullback, with the 30-day share price return down 3.29%. The 90-day move is up 6.91%, and the year-to-date share price return is 15.47%, while the 1-year total shareholder return sits at 34.37%...

Detailed price information for Argenx Se ADR (ARGX-Q) from The Globe and Mail including charting and trades.

September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company’s Board of Directors. “We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. Our focus at argenx today remains as

Detailed price information for Argenx Se ADR (ARGX-Q) from The Globe and Mail including charting and trades.

TORONTO, September 02, 2026--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation led by argenx's own scientists, the agreement represents a significant milestone in BenchSci's expansion across European biopharma.

This biotech innovator could be in only the early chapters of its success story.

September 1, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference. Fireside chat on Tuesday, September 8, 2026 at 9:30 a.m. ET in Boston, MA.Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY. A li

Argenx stock has delivered very strong gains over the past five years, yet current valuation checks suggest investors are paying a premium rather than buying into an obvious bargain. A 209.7% return over 5 years points to a stock where expectations have risen sharply and pricing now embeds a lot of optimism. Positive Phase 3 data for Vyvgart Hytrulo in autoimmune myositis can support high growth expectations, while execution and clinical risk around expanding the immunology pipeline may...

argenx (ENXTBR:ARGX) is back in focus after reporting positive topline results from the ALKIVIA Phase 3 trial of VYVGART Hytrulo in autoimmune myositis, a rare muscle disease with limited targeted treatment options. argenx shares have reacted strongly around these developments, with a 30 day share price return of 17.54% and a 90 day share price return of 26.80%. The 1 year total shareholder return of 50.58% and 5 year total shareholder return of 209.69% suggest that momentum has been building...

argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment. FB102 is expected to be integrated into argenx's existing research and development programs focused on immunology. For readers who want more ideas in advanced immunology and related technologies, the next step is to explore 134 healthcare AI...

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. (“Forte”) (Nasdaq: FBRX). The acquisition expands argenx’s portfolio of differentiated immunology medicines, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concep

Argenx shares rally as UBS issues a bullish note. Here’s how high its analyst expects ARGX stock to fly in 2026.

This biotech leader continues to rack up clinical successes.

Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.

argenx SE (NASDAQ:ARGX) delivered a clearly positive headline result from the Phase 3 ALKIVIA trial. VYVGART Hytrulo produced a 15.4-point mean advantage over placebo on the Total Improvement Score, or TIS, at Week 52 in the combined immune-mediated necrotizing myopathy and dermatomyositis population. The difference was statistically significant, with a p-value of 0.0011. The result […]

2026-08-20. The following slide deck was published by argenx SE in conjunction with this event.

Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in […]

Detailed price information for Argenx Se ADR (ARGX-Q) from The Globe and Mail including charting and trades.

Argenx's (ARGX) latest myositis data strengthened the outlook for efgartigimod, particularly in immu

argenx recently reported that its ALKIVIA Phase 3 trial of VYVGART Hytrulo in adults with autoimmune myositis met its primary endpoint, with patients showing statistically significant and clinically meaningful improvements in Total Improvement Score over 52 weeks versus placebo and a safety profile consistent with prior studies. A key insight is that this is the first Phase 3 study to show such benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies,...

Argenx’s Vyvgart Hytrulo could provide IMNM autoimmune myositis patients a treatment option.

argenx (NASDAQ:ARGX) reported positive topline results from its Phase 3 ALKIVIA trial of VYVGART Hytrulo in adults with autoimmune myositis, with the study meeting its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population. The Phase 3 ALKIVIA trial produced a statistically significant 15.

argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM. The study evaluated e